Powered 500 · 2026POWEREDS. 273 of 500
Under Ricks, Eli Lilly's early bet on GLP-1 drugs Mounjaro and Zepbound propelled the company from mid-tier pharma to the world's most valuable pharmaceutical company, with a market cap exceeding $800 billion.
David Ricks is Chairman and CEO of Eli Lilly, which has surpassed an $800 billion market capitalization driven by its GLP-1 drugs Mounjaro and Zepbound for diabetes and obesity.
Analysts project the GLP-1 market could exceed $100 billion annually. Under Ricks, Lilly has expanded investment in metabolic diseases, oncology, and neuroscience, transforming from a mid-tier pharma into the industry's market cap leader.
Interview · In Pipeline
Sponsored placement
An invitation, extended to Powered readers.
Drive the Continental GT S.
Request a test driveBentley T&Cs apply
